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Abstract
In human systemic lupus erythematosus (SLE), diverse autoantibodies accumulate over years before disease manifestation.
Unaffected relatives of SLE patients frequently share a sustained production of autoantibodies with indiscriminable
specificity, usually without ever acquiring the disease. We studied relations of IgG autoantibody profiles and peripheral
blood activated regulatory T-cells (aTregs), represented by CD4
+CD25
bright T-cells that were regularly 70–90% Foxp3
+.W e
found consistent positive correlations of broad-range as well as specific SLE-associated IgG with aTreg frequencies within
unaffected relatives, but not patients or unrelated controls. Our interpretation: unaffected relatives with shared genetic
factors compensated pathogenic effects by aTregs engaged in parallel with the individual autoantibody production. To
study this further, we applied a novel analytic approach named coreferentiality that tests the indirect relatedness of
parameters in respect to multivariate phenotype data. Results show that independently of their direct correlation, aTreg
frequencies and specific SLE-associated IgG were likely functionally related in unaffected relatives: they significantly
parallelled each other in their relations to broad-range immunoblot autoantibody profiles. In unaffected relatives, we also
found coreferential effects of genetic variation in the loci encoding IL-2 and CD25. A model of CD25 functional genetic
effects constructed by coreferentiality maximization suggests that IL-2-CD25 interaction, likely stimulating aTregs in
unaffected relatives, had an opposed effect in SLE patients, presumably triggering primarily T-effector cells in this group.
Coreferentiality modeling as we do it here could also be useful in other contexts, particularly to explore combined
functional genetic effects.
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Introduction
IgG autoantibodies are the diagnostic hallmark of Systemic
Lupus Erythematosus (SLE). They show particularly high affinity
for nucleic acid (dsDNA) as well as for nuclear and cytoplasmic
proteins that physically interact with nucleic acids, although
individual reactivity patterns are highly heterogeneous. Autoanti-
body generation, in part originating from inappropriately
processed self-antigens [1], is clearly T cell-dependent and occurs
during germinal center reactions leading to a high degree of
somatic hypermutation [2]. In these reactions, T- and B-cell
targets can diversify by intra- and intermolecular epitope
spreading, a mechanism in which crossreactivity and aberrant
interactions between specific T- and B-cells favor the selection of
self-reactive B-cells. Epitope spreading in SLE appears primarily
triggered by reactivity to Ro60/SSA and Sm/nRNP autoantigens
[3–6]. SLE-type autoantibodies accumulate and diversify over
many years before SLE is diagnosed [7]. These autoantibodies,
however, do not necessarily indicate manifest disease, and self-
reactive IgG with specificities indistinguishable from SLE patients
is frequently found in their healthy relatives [8–10]. These
unaffected relatives obviously share a genetic disposition to
produce SLE-associated autoantibodies [10], although they
usually remain disease-free for life.
Effector T-cells undergo regulation by Foxp3
+ regulatory T-
cells (Treg), which have raised extraordinary interest since it was
demonstrated that their deficiency, depletion or alteration results
in lymphoproliferative and autoimmune disorders in many
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33992contexts. Activated CD4
+Foxp3
+CD25
bright Tregs (aTreg), recent-
ly characterized in humans [11], express high levels of CD25, the
specific a subunit that defines the high-affinity IL-2 receptor. It is
well established that IL-2 produced by activated CD4
+ effector T-
cells is essential for maintenance and proliferation of
Foxp3
+CD25
bright Tregs [12]. Consequently, mice deficient for
IL-2 [13,14], CD25 [15], or the IL-2 receptor b subunit [16],
developed uncontrolled lymphoproliferation and lethal autoim-
munity. In human SLE, a relative deficiency of IL-2 production in
activated T-cells, by a mechanism of transcriptional repression, is
well documented [17], and a functional relevance of impaired IL-2
production was directly demonstrated for lupus manifestation in
NZB/W F1 mice [18], as it had been for other mouse
autoimmunity models [19]. Accordingly, indications of Treg
abnormalities in human SLE, such as reduced frequencies of
aTregs [20–23] as well as reversible impairment of their
functionality [24] have repeatedly been reported. Particularly, a
characteristically increased population of CD4
+Foxp3
+ cells with
low or absent surface CD25 [25,26] and reduced suppresive
capacity, but maintaining other Treg properties [27,28] has
pointed to an altered role of IL-2. Treg frequencies measured on
the basis of high surface CD25, thus representing functionally
active Tregs, were also found negatively correlated with anti-
dsDNA antibodies [23] and disease activity [22]. We have
previously reported the heritability of Treg frequencies in SLE-
affected families [29]. However, unaffected relatives of SLE
patients with SLE-type autoantibody reactivity have never been
studied for properties of T-cell regulation. This is the subject of the
present study: to investigate Tregs and their relationship with
autoantibodies and IL-2 in unaffected relatives compared to the
SLE patients themselves as well as to unrelated control subjects.
Given the uncharacterized heterogeneity of autoantibody
patterns in unaffected relatives [8], in order to interpret their
collective properties, a systematic broad-ranged study appeared
appropriate. An adequate method for this, which will be used here
in addition to specific IgG measurements, is the parallel and
quantitatively standardized assessment of a multitude of autore-
active IgG specificities by quantitative immunoblot [30], as it has
previously been applied to characterize antibody profiles in
different contexts in animal [31–34] and human [35–39] studies.
Furthermore, human genetic polymorphisms are deeply informa-
tive and regularly allow to identify risk factors for disease, but their
use to study specific molecular or cellular mechanisms is very
limited. A new analytical method, developed by us and named
coreferentiality [40], will be used here to identify and characterize
IL-2/CD25-mediated effects on broad-scale autoantibody profiles,
through the analysis of genotypes in the loci encoding IL-2 and
CD25.
We report the novel finding that various IgG autoantibody
measures were consistently positively correlated with aTreg
frequencies in unaffected relatives. We interpret these correlations
as the result of a mechanism of efficient compensatory T-cell
regulation, with a likely role of IL-2, that breaks down in manifest
SLE. Coreferentiality analysis, allowing to test the functional
relatedness of two parameters not in terms of direct correlation but
in respect to multivariate reference data, was used to indirectly
examine IL-2-mediated effects in this context through an analysis
of genetic variation in the IL2 and IL2RA (CD25) loci. In our
unaffected relatives, we detected significant coreferentiality
between genetic variants in these two loci in respect to
immunoblot autoantibody profiles. Subsequently modeling the
functional effect of IL2RA genetic variation and relating it to aTreg
frequencies, it turned out that IL-2-CD25 interaction was indeed
likely to trigger aTregs in the unaffected relatives, while in SLE
patients IL-2/CD25-mediated effects were rather opposed to
aTreg effects, supporting the notion that IL-2 triggered primarily
T-effector cells in manifest SLE. More generally, we argue that the
coreferentiality method has the power to model combined
functional genetic effects, which may be very useful in many
respects.
Results
1. Multispecific and SLE-associated IgG autoantibody
reactivity in unaffected relatives is intermediate between
SLE patients and unrelated control subjects
We assessed quantitatively standardized immunoblot profiles of
plasma IgG autoantibody reactivity from 128 SLE patients, 215
unaffected relatives and 140 healthy control subjects (listed in
Table 1) to electrophoretically separated protein extracts of
nuclear and cytoplasmic fractions of HEp2 cells as well as of
human brain proteins. In these three immunoblot assays,
performed in parallel for all subjects studied, plasma samples
were diluted so that they had identical total protein concentra-
tions. Reactivity patterns revealed on one of a total of 72
membranes are shown in Fig. S1. We could distinguish 46 separate
reactivity bands to HEp2 cytoplasmic proteins, 38 to HEp2
nuclear proteins and 46 to brain proteins, adding up to a total of
130. They were densitometrically quantified and standardized (see
methods). For each of the three extracts, we determined the band
number recognized by IgG in each plasma sample. While SLE
patients always recognized the highest median number of bands,
unaffected relatives also recognized a significantly higher band
number than unrelated healthy control subjects in all three
extracts (Fig. 1 A,C,E). In order to consider the quantitative
intensity of reactivities, we further calculated principal compo-
nents from the measured density quantitations of all bands
detected in the three extracts, respectively. The resulting first
principal components fitted 38% (HEp2-cytoplasm), 22% (HEp2-
nucleus) and 17% (brain) of the respective total variance, and their
factor loads were generally positive, so that factor-1 (F1) scores
could be interpreted as representations of fitted overall reactivity.
F1 distributions showed principally the same properties as band
numbers (Fig. 1 B,D,F), with F1 scores significantly discriminating
unaffected relatives from unrelated control subjects in terms of
reactivity to both HEp2 extracts, while not to in respect to brain
proteins. We finally performed quantitative ELISAs for plasma
IgG binding to dsDNA, Ro60/SS-A, Sm and nRNP autoantigens,
where samples were assayed with identical total protein concen-
tration as in the immunoblots. Also in these antigen-specific assays,
the unaffected relatives gave results intermediate between SLE
patients and unrelated healthy subjects. Their difference to the
control group was significant for IgG anti-dsDNA and anti-Sm
(Fig. 1 G,H,I,J). Anti-dsDNA and anti-Ro60/SS-A assays were
already reported for a subset of the present samples in our previous
heritability study [10].
Table 1. Sample characterization.
SLE Patients Unaff. Relatives Controls
Total 128 215 140
Gender 116 F, 12 M 129 F, 86 M 74 F, 66 M
Age (Median) 14–78 (37) 6–84 (38) 19–65 (43)
doi:10.1371/journal.pone.0033992.t001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33992Figure 1. IgG autoreactivities in SLE patients, unafffected relatives and unrelated control subjects. A–F: Band numbers and 1st principal
component calculated from HEp2 anti–cytoplasmic (A,B), anti-nuclear (C,D) and anti-brain (E,F) imunoblot reactivities. G–J: Specific SLE-associated
autoreactive IgG quantified by ELISA. All plots show group-wise medians and results of pairwise Mann-Whitney tests for differences between groups.
doi:10.1371/journal.pone.0033992.g001
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and frequencies of circulating active regulatory T-cells in
unaffected relatives
In a major subset of the subjects studied for autoantibodies (56
SLE patients, 123 unaffected relatives and 87 healthy controls), we
parallelly stained peripheral blood mononuclear cells (PBMC),
freshly isolated together with the plasma, for flow-cytometric
analysis in order to quantify active regulatory T-cells (aTregs).
Results from these experiments have been published earlier in the
context of a genetic study [29]. Following the way how human
Treg subsets were recently functionally tested and their activity
validated on the basis of differential surface CD25 density [11], we
quantified aTregs as CD25
bright within CD4
+ T-cells. In order to
consider the frequency of circulating aTregs in an unbiased way,
we used an objectively defined threshold criterion (see methods).
We particularly made sure by confirmatory stainings of 15 SLE
patients, 45 unaffected relatives and 54 controls with combined
CD25 and intracellular Foxp3 that the used CD25
bright gate
regularly represented highly enriched Foxp3+ cells in all three
subject groups (8168% in SLE patients, 79611% in relatives and
74613% in controls, also see methods and Fig. 2 for represen-
tative cytometric profiles). Differences in the resulting aTreg
frequencies between SLE patients, unaffected relatives and
unrelated controls were not significant. However, aTreg cell
frequencies had highly significant positive correlations with the
band numbers of IgG autoantibodies reactive toward HEp2
nuclear and cytoplasmic proteins when calculated within the SLE-
unaffected relatives group (Fig. 3, Table 2), in contrast to SLE
patients or unrelated control subjects. Similarly significant positive
correlations exclusively within the relatives group were also found
between aTreg frequencies and all measured SLE-associated
plasma IgG autoantibodies: anti-dsDNA (within unaffected
relatives: RSpearman=+0.23 [P=0.01]), anti-SSA (RSpearman=+0.24
[P=0.007]), anti-Sm (RSpearman=+0.40 [P=8E-6]), and anti-nRNP
(RSpearman=+0.31 [P=0.0006]), but not IgM anti-dsDNA (Fig. 4,
Table 2). To confirm this result, we further calculated within-
group correlations with each of the quantitative densities of the
130 detectable immunoblot bands separately, and tested the
group-wise medians of the resulting 130 correlation coefficients
against respective permutation-based null distributions (Fig. 5A). A
difference from zero was only detected for the unaffected relatives
group. These correlations became even stronger when using
weighted correlations, considering each family with equal weight
in order to avoid bias due to overrepresentation of families with
many relatives. The highest correlation coefficients clearly came
from IgG reactivities to HEp2-cytoplasmic antigens.
For comparison, we analyzed analogous group-wise correlations
of SLE-associated specific IgG with the same panel of immunoblot
reactivities. In contrast to those of the aTreg frequencies,
correlations calculated for IgG anti-Sm were very strong in the
patients group (Rmedian,weighted=+0.26; PPerm,0.001) but insignificant
for unaffected relatives (Fig. 5B), despite the fact that the latter had
an almost equal reactivity to Sm. Similar median correlations as
for anti-Sm were found for IgG anti-nRNP (significant only for
patients: Rmedian,weighted=+0.17; PPerm,0.001), while IgG anti-
Ro60/SSA rather behaved like aTreg frequencies and showed
significant positive median correlations only in the relatives
(Rmedian,weighted=+0.11; PPerm=0.002) and also in the control group
(Rmedian=+0.10; PPerm=0.001).
In summary, we interpreted these findings so that unaffected
relatives were likely to bear a particular regulatory capacity that
involved compensatory expansion of aTregs in parallel to their
individual extent of multispecific IgG autoantibody production,
including SLE-related and other specificities. These aTregs could
be triggered either by autoantibodies or by signals from B-cells
and/or T-helper cells involved in their production. The SLE
patients’ multispecific autoreactive IgG repertoire, in contrast, was
not obviously related to aTregs but instead strongly related to
SLE-specific IgG such as anti-Sm and anti-nRNP, in consistence
with the epitope spreading concept [5,6].
3. Coreferentiality: a new approach to functional
relatedness
Correlation does not necessarily reflect functional relatedness,
neither is it always observed when two variables are functionally
related, i.e., when they have impacts on the same effect. In order
to address the functional relations between IgG autoantibodies
and aTregs in our unaffected relatives, we developed a new
approach to detect functional relatedness irrespectively of direct
correlations. Self-reactive immune repertoires capable of trigger-
ing aTregs in unaffected relatives could be either natural or
originating from the recognition of SLE-related autoantigens, by
crossreactivity or epitope spreading. In both cases they likely
included a broad and diverse spectrum of specificities, i.e., a
substructure inside self-reactive repertoires. We could, therefore,
expect that the more a specific measurable parameter was
functionally related to the mechanisms that shaped the described
relation between aTregs and self-reactive IgG, the more it would
relate to the same substructure inside the entire self-reactive
repertoire as aTreg frequency did. This could be tested by
comparing how two parameters (here: aTreg frequency and a
second parameter to be tested) respectively related to a
standardized multivariate dataset representative for self-reactive
immune repertoires, e.g., our 130 quantitatively standardized
immunoblot IgG reactivities. A test criterion for specific
relatedness between the two parameters could then be formulated
as follows: were they correlated with the same elements inside the
reference system in the same way, i.e., did they behave coreferentially
toward it ? Mathematically, coreferentiality between two test
parameters can be formulated as a second-order correlation
between two vectors containing correlation coefficients of each
respective test parameter with the vector of the multiple reference
variables [40], and its statistical significance tested by comparison
to a null distribution generated by data permutations. Using a test
that is principally robust against direct correlations through
parallel permutation of the two test parameters, we have found
a remarkable power of this method in simulated data [40]. This
allows us here to interpret coreferentiality as an independent
indicator of relatedness.
We first wanted to know if particular repertoire substructures
were functionally related to aTregs. Were proteins originating
from the three different antigen sources (nuclear, cytoplasmic,
brain) equally involved in our hypothesized feedback regulation or
not ? The coreferentiality criterion was appropriate to answer this,
formulated as follows: would the same among the 130 immunoblot
reactivities that correlated most positively with aTreg frequencies
also correlate most positively with the diversity, i.e., the recognized
band number, of IgG reactive toward each given antigen source,
and vice versa ? Coreferentiality with aTreg frequencies was tested
accordingly, separately within the groups of SLE patients,
unaffected relatives and unrelated healthy controls. Weighted
first-order correlations were used in order to correct for unequal
representations of families. While no significant coreferentiality
was found for any of our three band number counts within
patients or unrelated control subjects, it was highly significant
within the unaffected relatives group, but exclusively for the
diversity of IgG to HEp2-cytoplasmic proteins. Analogously, we
asked whether aTreg frequencies were coreferential with SLE-
SLE Compensation in Unaffected Relatives
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significance within SLE patients or the unrelated control group,
while log-transformed IgG anti-dsDNA, anti-SSA, and anti-Sm
measures showed significant coreferentiality within the unaffected
relatives (Table 3, Fig. 6). We did not detect ‘bystander
coreferentiality’ [40] (also see methods) in any significant test. This
demonstrated that the coreferentiality approach was capable of
revealing immune repertoire substructures. In fact, a particular self-
reactive substructure appeared functionally related to T-cell
regulation in unaffected relatives, involving the IgG recognition of
diversecytoplasmicproteinsalong withSSA/Ro60,dsDNAand also
Sm - highly recognized by the relatives, but directly correlated with
multispecific IgGs rather in the patients than the relatives group.
4. Genotype coreferentiality: an approach to the role of
IL-2-CD25 interaction
Next we wanted to apply the coreferentiality approach to
interpret the role of a molecular mechanism with evident
Figure 2. Systematic gating for CD25
bright aTregs. A. First, in order to specify the upper limit of CD25 staining in conventional T-cells for each
sample, the ninety-ninth percentile of PE/Cy5 fluorescence intensity within CD4
2CD45RO
2 cells (a population containing no Tregs) was determined
as gate A. CD4
+CD25
bright aTregs in the same sample were then quantified as those CD4
+ cells that exceeded this value at least three-fold (gate B). B–
D. The CD25
bright gate (B) contains high proportions of Foxp3+ cells in samples from SLE patients, unaffected relatives and healthy control subjects.
As exemplified by an active SLE patient (panel B), an unaffected relative (panel C) and a healthy control subject (panel D), the CD25
bright gate B
defined as 3xMFI(gate A) regularly contained 70–90% Foxp3+ cells within CD4+ lymphocytes when additional samples were stained for the same
markers as previously but now in combination with intracellular Foxp3 staining.
doi:10.1371/journal.pone.0033992.g002
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interaction of IL-2 with CD25. If our above interpretation was
correct and CD25
bright aTregs were compensatorily expanded in
unaffected relatives and exerted a regulatory feedback function, we
could readily expect that this effect depended on IL-2-CD25
interaction. To test if a functional context of IL-2, CD25 and
aTreg effects in our unaffected relatives was related to a particular
immune repertoire structure, we chose an approach based on the
obvious fact that IL-2 and CD25 are closely functionally related.
Therefore, if the coreferentiality approach was valid and
sufficiently powerful, we could expect to detect coreferentiality.
Thus, would the respective functionalities of IL-2 and CD25 be
coreferential in respect to our multivariate reference system of
autoreactive IgGs, indicating that IL-2-CD25 interaction influ-
enced the self-reactive IgG repertoire in a defined manner ? And if
so, was this effect related to T-cell regulation ? Unfortunately, IL-2
itself largely escapes meaningful measurement due to its local effect
and short life span. Also the physiologic functionality of CD25 in
lymphatic organs is not clearly reflected by measures in conditions
where they are feasible, namely the use of peripheral blood cells.
In contrast, genetic variation can easily and accurately be assessed,
and does not vary with measurement conditions. Polymorphisms
with likely functional effects have indeed been described for both
the loci IL2 and IL2RA encoding CD25 (see discussion). Since
genotypes are furthermore individually invariant and independent
of phenotypic effects, coreferentiality between genetic effects could
be expected to be particularly robust. Hence, we first aimed to find
out whether IL2 genetic variation behaved coreferentially in
respect to IgG repertoires with genetic variation in the IL2RA
locus, independently of aTregs.
In the relatively small IL2 locus, two SNPs have been most
studied: rs2069762, located within the promoter region and
associated to differences in IL-2 production by cultured cells [41],
and rs2069763, synonymous-coding in the first exon, the minor
allele of which was recently found protective against SLE in a
Chinese population [42]. We typed these two and six other SNPs
covering the IL2 locus and the 59 and 39 flanking regions (see LD
map, Fig. S2). Among the additional six SNPs, two had low minor
allele frequencies below 5%, and two others were in strong LD
with rs2069763, while the remaining two, rs1479924 and
rs11575812, formed a new linkage group in almost complete LD
(R
2=0.94) although located 59 and 39 of the coding region,
respectively. We further found that for rs11575812, rs2069762 and
rs2069763, each respective minor allele very likely represented an
independent locus-spanning haplotype (see discussion), which is
compatible with the fact that rs11575812 and the strongly linked
rs1479924 are located at opposite sides of the locus. To cover the
much larger IL2RA locus, we typed 25 SNPs (Table S1), including
Figure 3. Correlations between CD25
bright/CD4
+ aTreg frequencies and immunoblot band numbers. A–C: Bands recognized in
immunoblots of HEp2-cytoplasmic proteins by SLE patients, unaffected relatives and unrelated control subjects. D–F: Bands recognized in
immunoblots of HEp2-nuclear proteins. Regression lines represent linear regression.
doi:10.1371/journal.pone.0033992.g003
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been reported [43]. We first tested coreferentiality in unaffected
relatives, for the scores of rs11575812, rs2069762 and rs2069763,
respectively, with all 25 IL2RA SNPs simultaneously by data
permutations. Surprisingly, we found a particularly strong
coreferentiality for rs11575812 (|RC|max=0.6; PPerm=0.044).
Table 2. Group-wise Spearman rank correlations with CD25
bright/CD4
+ frequencies.
Within Group SLE Patients Unaff. Relatives Controls
RSpearman PSpearman RSpearman PSpearman RSpearman PSpearman
Recognized IgG bands to HEp2-cytoplasmic
proteins
20.03 0.826 +0.34 0.0002 +0.03 0.768
Recognized IgG bands to HEp2-nuclear
proteins
+0.07 0.622 +0.34 0.0002 +0.06 0.597
Recognized IgG bands to human brain
proteins
+0.05 0.732 +0.17 0.061 20.11 0.318
IgG anti-dsDNA 20.17 0.217 +0.23 0.011 20.10 0.399
IgG anti-Ro60/SSA 20.17 0.220 +0.24 0.007 20.05 0.654
IgG anti-Sm 20.11 0.400 +0.40 0.000008 +0.02 0.827
IgG anti-nRNP 20.06 0.648 +0.31 0.0006 +0.04 0.709
IgM anti-dsDNA +0.11 0.407 +0.08 0.364 20.07 0.543
doi:10.1371/journal.pone.0033992.t002
Figure 4. Correlations between aTreg frequencies (CD25
bright/CD4
+) and quantified SLE-associated specific autoreactive IgG. A–C:
IgG anti-dsDNA. D–F: IgG anti-Sm. Regression lines represent linear regression.
doi:10.1371/journal.pone.0033992.g004
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IL2-IL2RA coreferentiality in the relatives group is
plausible in several respects and group-independent
The finding that functional effects of genetic variation in the IL2
and IL2RA loci indeed parallelled each other in the unaffected
relatives in their relations to self-reactive repertoires, together
with the evidence for strong immune regulation in this group,
prompted us to use coreferentiality as a modeling tool. Since
transcriptional regulation of IL-2 is known to be complex and
specifically affected by SLE [17], we particularly sought to derive a
model for functional genetic effects in the IL2RA locus. We did this
by maximizing the coreferentiality between two functions
representing linear combinations of (a) the three principal IL2
SNPs (rs11575812, rs2069762, rs2069763) and (b) five represen-
tative IL2RA SNPs (see methods). The optimized model reached a
Figure 5. Unweighted and family-weighted correlation coefficients. Distributions of unweighted and family-wighted correlation coefficients
of CD25
bright/CD4
+ aTreg frequencies (A) and log-transformed IgG anti-Sm (B) with all 130 single immunoblot reactivities are shown within SLE
patients, unaffected relatives and unrelated controls, respectively. Reactivities to cytoplasmic bands are indicated by filled circles, anti-nuclear
reactivities by triangles and anti-brain reactivities by crosses. Annoteted P-values were calculated by the described permutation test.
doi:10.1371/journal.pone.0033992.g005
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33992coreferentiality of RC max=0.77, maximized by functions with the
following normalized coefficients for (a) IL2 and (b) IL2RA SNP
scores:
(a) 20.88[rs11575812]+0.03[rs2069762]20.47[rs2069763];
(b) 20.33[rs791589]+0.15[rs706778]+0.51[rs7073236]20.77[r-
s10795791]+0.14[rs11594656].
In order to test whether the observed degree of optimized
coreferentiality was meaningful or could also be achieved
accidentally, we optimized 50 further models with the same
method but using random data permutations instead of our real
data (the usual 1,000 permutations being impossible to perform
here due to computational time). In this null distribution of
models, only two out of 50 gave maximized coreferentialities
reaching the value of 0.77 found for the true data, corresponding
to an empirical significance of P=0.04. Thus, the derived model
was likely non-random and meaningful, and we proceeded to
analyze its properties.
In order to score the respective functional IL2 and IL2RA
genetic effects according to this optimization, we calculated both
model scores for all typed unaffected relatives from functions (a)
and (b), respectively. IL2 and IL2RA model scores were not
significantly correlated with each other (RSpearman=0.08; P=0.26),
excluding a trivial interpretation of the achieved coreferentiality by
an artificial score correlation. Next, we wanted to know whether
the resulting IL2RA model was compatible with an effect related to
T-cell regulation as it was suggested above. Cytometric aTreg
frequencies, which had not been used to derive the IL2-IL2RA
effects model, could in fact now be used to test this: correlated with
self-reactive IgG and coreferential with repertoire substructures as
shown above, were they also coreferential with the independently
modeled IL2RA genetic effect in the unaffected relatives group ?
Indeed, we found a significant coreferentiality of RC=+0.39
(PPerm=0.025, see also Fig. 7) with no bystander effect. This
supported the meaningfulness of the model and also allowed to
interpret its score resulting from function (b): if CD25 had a
parallel functional effect with aTregs on autoantibody repertoires,
then given a positively signed RC, the model score indicated a
positive effect on CD25 expression and/or functionality.
If our model was valid, the modeled genetic CD25 effects on
autoantibodies with a role in immune regulation had to depend on
specific antigen recognition by CD4
+ T-cells. A straightforward
way to test this was whether our model was also related to genetic
Figure 6. Group-wise coreferentialities with aTreg frequencies, in respect to 130 IgG immunoblot reactivities as reference data. A–C:
Coreferentiality between CD25
bright/CD4
+ aTreg frequencies and IgG anti-HEp2-cytoplasmic immunoblot band numbers. D–F: Coreferentiality
between aTreg frequencies and log-transformed IgG anti-Ro60/SSA. G–I: Coreferentiality between aTreg frequencies and log-transformed IgG anti-
Sm. Reactivities to cytoplasmic bands are indicated by filled circles, anti-nuclear reactivities by triangles and anti-brain reactivities by crosses.
doi:10.1371/journal.pone.0033992.g006
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+ T-cell
repertoire. Therefore, we determined and scored seven major
HLA-DR types. Tested cumulatively, there was significant
coreferentiality with our IL2RA model score within unaffected
relatives (Table 4), but not with aTreg frequency or any of our
autoantibody measures (not shown). Univariately, HLA-DRB1*04
and DRB1*13 were significant for positive, and DRB1*01 for
negative coreferentiality with the IL2RA model score, suggesting
that these HLA types had effects on autoreactive IgG in the
unaffected relatives resembling that of stronger or weaker CD25
functionality. We also analyzed analogously whether the modeled
genetic CD25 effect was coreferential with specific SLE-associated
autoantibodies that had shown significant correlations and
coreferentiality with aTreg frequencies. This, however, was not
the case: coreferentiality (as well as direct correlations, not shown)
of the model score with specific IgG measures or the IgG band
number detected to HEp2-cytoplasmic proteins remained insig-
nificant. In contrast, it was significant with the IgG band number
toward HEp2-nuclear proteins (Table 4).
IL2-IL2RA coreferentiality maximization in the patients group,
in contrast to the relatives, yielded a low value (0.57) and was
therefore not followed. However, while the transcriptional control
of IL-2 is known to be altered in SLE pathology [17], there is no
such indication for CD25, so that a valid model for functional
genetic effects likely represented them in all individuals. If this was
the case for our IL2RA model optimized for the unaffected
relatives, it should be applicable also beyond that group. Indeed,
model scores calculated with function (b) from genotypes of
patients or unrelated controls showed the same principal
relatedness with the dominant IL2 SNP rs11575812: coreferenti-
ality (RC=20.66 for the unaffected relatives) was equally signed
and reached statistical significance when calculated within patients
(RC=20.37; PPerm=0.033). It was also equally signed in the
control group (RC=20.11) although not significant. Next,
addressing the relation of our IL2RA model with TCR-dependent
cell activation, it was not coreferential with HLA-DR types in SLE
patients as it had been in the unaffected relatives (Table 4). For
other reasons, we had typed our subjects for 24 SNPs covering the
Table 3. Coreferentialities with CD25
bright/CD4
+ frequencies.
Within Group SLE Patients Unaff. Relatives Controls
RC PPerm*R C PPerm*R C PPerm*
Recognized IgG bands to HEp2-cytoplasmic
proteins
20.13 0.491 +0.61 ,0.001 +0.04 0.792
Recognized IgG bands to HEp2-nuclear proteins 20.14 0.498 +0.36 0.257 +0.23 0.232
Recognized IgG bands to human brain proteins +0.20 0.375 +0.24 0.694 20.04 0.794
log IgG anti-dsDNA 20.12 0.589 +0.59 0.019 20.03 0.904
log IgG anti-Ro60/SSA 20.16 0.314 +0.74 0.002 +0.18 0.185
log IgG anti-Sm 20.03 0.848 +0.48 0.005 +0.00 0.987
log IgG anti-nRNP 20.09 0.635 +0.30 0.212 +0.13 0.401
log IgM anti-dsDNA 20.17 0.557 +0.34 0.055 +0.30 0.066
*Significance according to permutation test (see methods). Effects of bystander coreferentiality were checked for all significant tests (see methods), but rates of
simulated bystander data reaching the respective test significance never exceeded 5%.
doi:10.1371/journal.pone.0033992.t003
Figure 7. Group-wise coreferentialities between CD25
bright/CD4+ aTreg frequencies and IL2RA genetic-effects model scores. A: SLE
patients, B: unaffected relatives, C: unrelated controls. Reactivities to cytoplasmic bands are indicated by filled circles, anti-nuclear reactivities by
triangles and anti-brain reactivities by crosses.
doi:10.1371/journal.pone.0033992.g007
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TCR signal transducer that is characteristically downregulated
and replaced in SLE T-cells [44], which is a causal factor for
transcriptional IL-2 repression [45]. Testing our IL2RA model for
coreferentiality with the cumulated CD247 SNPs, we found
similarly high locus-wise maximal coreferentialities for all three
groups (Table 4), significant for patients and for the control group
as well as when calculated in all three groups merged
(|RC|max=0.49; PPerm=0.040). We also found significant positive
coreferentialities with IgG anti-Sm and anti-nRNP in the control
group. If our IL2RA model was generally representative for IL2RA
functional genetic effects and functionally related to CD3f effects,
we further expected that an IL2RA genetic effects model
independently optimized for CD247-IL2RA coreferentiality would
be close to that derived by IL2-IL2RA coreferentiality optimiza-
tion. Indeed, coreferentiality optimization within the unrelated
controls, using the same five IL2RA SNPs as above and three
CD247 SNPs, led to an IL2RA model with almost identical
coefficients, and scores that were more than 90% correlated with
those of the initial IL2-IL2RA model in all three subject groups
(Table 5).
6. Modeling suggests inverse IL-2 effects in patients and
unaffected relatives
Given the plausibility that our initial unaffected-relatives-
optimized IL2RA model represented the same IL2RA functional
genetic effects in all subjects, we finally tested whether it was
coreferential with cytometric aTreg frequencies in the SLE
patients group. Surprisingly, we found a significant negative
coreferentiality of RC=20.44 (PPerm=0.028), inversely signed in
respect to that found for the unaffected relatives (Fig. 7, Table 4),
and with no bystander effect. To confirm whether inverse IL2RA-
aTreg coreferentialities in patients and unaffected relatives were a
valid result, we optimized a second independent IL2RA model for
coreferentiality between the five initially used IL2RA SNP scores
and aTreg frequency in the SLE patients group, and found that
this IL2RA model was also similar to the initial one as was that
optimized with CD247 SNPs in controls (Table 5).
Discussion
We describe here that unaffected relatives of SLE patients, who
frequently presented SLE-related IgG autoantibodies, showed
remarkable and consistently significant positive correlations of
their circulating active Treg frequencies with SLE-associated IgG
specificities as well as with reactivity band numbers directed
toward immunoblot-separated autoantigens. These positive cor-
relations were unique for the group of unaffected relatives, and
neither found in SLE patients nor in unrelated control subjects,
suggesting that they were a reflection of a compensatory feedback
mechanism that contributed to the prevention of overt disease in
unaffected relatives who shared genetic susceptibility factors for
SLE-associated autoantibody diversification. Such a mechanism
could be triggered by either certain autoantibodies themselves, or
by T-helper cells involved in their generation, and lead to an
expansion of aTregs with the capacity of controlling potentially
pathogenic effects. This is consistent with mouse lupus models,
where disease manifestation was found preceded by reduced Treg
numbers [46], accelerated by Treg depletion [47], and delayed or
Table 4. Coreferentialities of the IL2RA model score with other parameters.
Within Group Unaff. Relatives SLE Patients Controls
(optimized)
RC PPerm RC PPerm RC PPerm
Frequency CD25
bright/CD4
+ +0.39 0.025 20.44 0.028 20.03 0.866
CD247 (CD3Z) All typed SNPs* 0.57 0.118 0.51 0.041 0.57 0.023
log IgG anti-dsDNA 20.03 0.894 +0.36 0.112 +0.09 0.548
log IgG anti-Ro60/SSA +0.03 0.851 +0.21 0.247 +0.11 0.535
log IgG anti-Sm +0.40 0.156 +0.15 0.379 +0.37 0.014
log IgG anti-nRNP +0.34 0.099 +0.22 0.231 +0.37 0.003
log IgM anti-dsDNA +0.05 0.757 +0.49 0.010 20.17 0.237
Recognized IgG bands to HEp2-cytoplasmic
proteins
+0.14 0.574 +0.06 0.749 +0.28 0.067
Recognized IgG bands to HEp2-nuclear
proteins
+0.36 0.030 +0.32 0.084 20.28 0.066
Recognized IgG bands to brain proteins 20.04 0.947 20.06 0.696 +0.29 0.057
HLA-DRB1*01 Alleles 20.56 0.007 +0.18 0.416 (not typed)
HLA-DRB1*03 Alleles +0.25 0.282 +0.04 0.817 (not typed)
HLA-DRB1*04 Alleles +0.62 0.006 +0.00 0.978 (not typed)
HLA-DRB1*07 Alleles 20.37 0.097 20.18 0.372 (not typed)
HLA-DRB1*11 Alleles +0.33 0.129 +0.37 0.128 (not typed)
HLA-DRB1*13 Alleles +0.56 0.035 +0.09 0.593 (not typed)
HLA-DRB1*15 Alleles 20.09 0.838 20.01 0.971 (not typed)
All HLA-DRB1 types* 0.62 0.027 0.37 0.338
*Test for multiple parameters, on maximal absolute coreferentiality |RC|max (see methods). Significant tests, except those for multiple SNPs, were also checked for the
effect of bystander coreferentiality (see methods), but no such effect was detected.
doi:10.1371/journal.pone.0033992.t004
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extracted from young mice [48,49]. In human families affected
with SLE, healthy family members with elevated SLE-type
autoantibody reactivity were repeatedly reported [8–10,50],
without indication of being at high risk to develop SLE. These
autoantibody-positive unaffected relatives, however, were so far
systematically studied only for heritability, which was principally
confirmed for the autoantibody trait but remains unclear in
respect to specificities [8]. Healthy individuals with high levels of
virtually all SLE-associated autoantibody specificities were also
found in the general population, although at low frequencies
[51,52]. A mechanism of active Treg-mediated SLE compensation
in these individuals, as we suggest here, favors therapeutic
perspectives to either restore this compensation or prevent SLE
at an early stage by Tregs or Treg-supporting therapies.
We did not stain for Foxp3 in this study since intracellular anti-
Foxp3 staining, now regularly used to characterize Tregs, was not
available when the experiments were performed. Neither were
auxiliary Treg markers such as CD127 known. However, the way
we have studied aTregs appears accurate also in respect to current
knowledge, particularly since recent literature makes it more and
more likely that CD25 (gated with a high threshold) is a more
important marker for active Tregs than Foxp3: it has been well
demonstrated that a relevant subset of peripheral human
CD4
+Foxp3
+ cells that is increased in SLE and most character-
istically shows low or absent (but not bright) surface CD25, does
not consist of functionally active Tregs [11,25–28,53,54]. Our
objectively defined gate for CD25
bright aTregs efficiently excludes
this population, thus can be said to use CD25 as the Treg activity
marker as which the most recent literature characterizes it. At the
same time our aTreg gate enriched Foxp3
+ cells sufficiently and to
similar extents in the three groups studied, as confirmatory Foxp3/
CD25 stainings show (see methods, Fig. 2 and Fig. S3).
Particularly, there was no indication of increased contamination
of the gated CD25
bright cells by Foxp3
2 T-cells in SLE patients
that could theoretically occur in presence of disease-related
Foxp3
2 T-cell activation, which was once reported especially for
patients with highly active disease [55]. Also other studies that we
have meanwhile performed indicate no significantly increased
surface CD25 in CD4
+Foxp3
2 cells of our SLE patients when
compared to controls (unpublished data).
IL-2 is commonly regarded as the most important maintenance
factor for Tregs [12]. Deficiency for either IL-2 or CD25, which is
the specific element of the high affinity IL-2 receptor that also
characterizes human aTregs, results in impaired Treg functionality
and autoimmunity in mice [13–15]. Dysregulation and relative
transcriptional repression of IL-2, in turn, have been well
documented in SLE [17]. Therefore it was straightforward for
us to address the question whether the hypothesized compensatory
mechanism in unaffected relatives was IL-2-related. To study this,
we used a novel approach, coreferentiality, to derive a model of
IL-2-mediated functional effects depending on genetic variation in
the IL2RA locus. The properties of the derived and empirically
validated model suggested that (i) the IgG autoreactive repertoire
was indeed significantly influenced by IL-2-CD25 interaction in
the unaffected relatives, and (ii) aTreg frequency in this group was
related to a similar substructure in the autoantibody repertoire as
was the modeled IL-2-CD25-mediated genetic effect: both were
coreferential, thus likely functionally related. Applied to SLE
patients, the same IL2RA genetic-effects model surprisingly showed
an inverse coreferentiality with aTreg frequency, indicating that
the modeled IL-2-mediated effects were functionally opposed to
aTreg effects. This is most easily explainable by the notion that IL-
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than aTregs.
This explanation is consistent with the known transcriptional
IL-2 repression in SLE, which, however, was so far rather seen
associated with altered effector cell activation. In any case it
appears to be part of a systemic T-cell pathology that includes
aspects of both hypo- and hyperactivity, i.e., more rapid but
dysregulated and less sustainable responses [44]. Altered or
deficient Treg functionality is in fact likely to be an important
and early aspect of this dysregulation. This is supported by the
now well-documented characteristic reduction or even absence of
surface CD25 on likely dysfunctional Tregs in SLE [26,27], which
was indicative for their known reduced suppressive function [24]
and ‘dissociated’ from the often proportionally increased Foxp3
expression in SLE [28,53]. Furthermore, in line with similar data
from diabetic NOD mice [56], a recent report demonstrates that
lupus pathogenesis in NZB/W F1 mice could be either accelerated
by IL-2 neutralization or impeded by IL-2 complementation [18],
and proposes a pathogenesis model driven by interdependent Treg
and IL-2 deficiencies. However, relative Treg deficiency rather
preceded IL-2-mediated effects in that study. The opposed effects
of IL-2 and aTregs in SLE patients suggested by our model
support the same notion that reduced IL-2 may not be directly
coincident with deficient regulation. Our present results also point
to separate factors contributing to Treg functionality in unaffected
relatives. Effects of IL2RA genetic variation in this group, although
related to the aTreg effects on autoantibodies, primarily concerned
an autoantibody repertoire that was clearly dependent on HLA-
DR types, focused on nuclear rather than cytoplasmic targets, and
showed no evident relation to SLE-associated specific IgG.
Unaffected relatives’ aTreg frequencies, however, were related to
an autoantibody profile with no evident HLA-DR dependency,
focused on cytoplasmic targets and also strongly coreferential with
the presence of SLE-associated specific IgG. This suggests that the
hypothesized compensatory mechanism that lead to the initially
observed positive correlations between autoantibodies and aTreg
frequency was not only driven by the IL-2-mediated repertoire
effects, but by an additional factor that was related to the
recognition of SLE-specific antigens and less HLA-dependent. In
summary, it appears plausible that strong IL-2-mediated effects
principally favor aTregs in immune reactions including natural self
antigens but without an apriori relation to SLE autoantigens, and
that the efficiency of this mechanism is a condition for SLE
compensation in genetically susceptible but healthy individuals.
Nevertheless, specific aTregs recognizing particular epitopes and
expanded or induced in SLE autoantigen-specific immune
reactions that also lead to the presence of SLE-type autoantibod-
ies, may well control the potentially pathogenic effects of these
reactions. SLE could become clinically manifest when this specific
compensatory regulation breaks down. In the compensated state,
IL-2 reduction or dysregulation might favor the loss of the specific
aTregs. In their absence, however, IL-2 could directly trigger
pathogenic effector functions. This could make potential IL-2
therapies a double-edged sword. It would, however, generally
encourage efforts to develop new therapies stabilizing or even
restoring the compensated state by supporting or expanding Tregs
with particularly relevant specificities.
In the context of the studied IL2 polymorphisms, the strongest
genetic effect in our model was attributed to the 39 SNP
rs11575812, which was in almost complete linkage with the far
59 rs1479924. To our knowledge, this linkage group has not been
described or considered in the context of association studies so far.
However, it showed a remarkable property that extends earlier
observations. Thus, an earlier study of the two traditionally typed
SNPs rs2069762 (59 promoter region, also referred to as 2384 or
2330) and rs2069763 (1st-exon synonymous-coding, +114) had
already noted that the haplotype consisting of the combined
respective minor alleles was inexistent [57]. Having typed
rs11575812 together with these two SNPs, we can confirm and
extend this observation: none of our 448 completely typed
individuals had more than two minor alleles of the three SNPs
combined, while 79% had exactly two. This indicates that in fact
no haplotype with more than one minor allele existed, and that
therefore each respective minor allele in these three polymor-
phisms represented an independent locus-spanning haplotype, an
interpretation that also explains the strong linkage between
rs11575812 and the distant rs1479924. In this context, the fact
that the haplotype defined by the rs11575812 variant, which
according to our model had the strongest functional effect, was not
considered in the earlier studies of genotype-function relationships
[41,57,58], might explain inconsistencies between them. Never-
theless, all found significant genetic effects. The only study
including IL-2 protein quantification [41] reported that the
presence of the rs2069762 minor G allele resulted in increased
IL-2 secretion by anti-CD3/CD28-stimulated T-cells, thus could
be ascribed a relatively positive effect on IL-2 functionality. Our
unaffected-relatives IL2 model ascribes negative functional effects
to the respective minor alleles of both rs11575812 and rs2069763,
but no effect to that of rs2069762. In the context of the
interpretation of all three minor alleles as independent haplotypes,
this is consistent with the previously described relatively positive
effect of rs2069762 G. These haplotype structures may have
particular functional relevance since IL-2 is monoallelically
expressed in single human T-cells [59], although not stably in
expanded clones [60]. IL2 is also since long suspected for
association with various disease phenotypes, but it has to be taken
into account that linkage in the IL2 locus (including the discussed
haplotype structure) extends to the neighboring IL21 gene and
therefore association does not necessarily reflect IL-2-mediated
effects. Association of the IL2-IL21 linkage region is in fact
established with autoimmune diseases such as type-1 diabetes [61],
psoriasis [62] and celiac disease [63], while it remains unconfirmed
for multiple sclerosis where rs2069762 had shown the strongest
trend [64,65]. Isolated association of rs2069763 with SLE was
reported for a Chinese population [42]. Also genetic variation in
the IL2RA locus has an evident functional relevance, clearly
demonstrated by its association with rheumatoid arthritis [66],
type-1 diabetes [43] and multiple sclerosis [65]. The two latter
studies each detected two separate genetic effects located 59 or in
the 59 portion of the coding region, which is the same region
where four of our five SNPs selected for the IL2RA model function
were located (selected by their coreferentiality with rs11575812).
Two had in fact the highest impacts in the resulting model
(rs7073236, rs10795791). One of the two IL2RA-region SNPs
suspected to be causal [43], rs11594656, actually had a high
coreferentiality with rs11575812 and was included in our model
function, but turned out to have little impact in the resulting model
(see also Table S1).
Perhaps the most interesting aspect of the present study is the
coreferentiality approach by itself, which we formally describe in
an accompanying publication [40]. Applying it and following the
principle whether principally known genetic effects were related
with similar substructures in a multivariate set of phenotype
variables, we were able to derive a model of combined genetic
effects that showed all signs of plausibility. This approach is new,
and we are not aware of publications describing anything similar.
Modeling the functionality of combined genetic effects is usually
beyond the scope and power even of large genetic studies, while
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it interesting to discuss the perspectives of our approach in respect
to genetics. Here it does in fact represent a strategy of investigation
that principally differs from convention, reverting priorities:
traditionally, genetic study first aims at the revelation of risk loci
independently of any functional hypothesis, only to be followed by
functionality-guided approaches toward detected risk factors,
either directly by experiments or indirectly by interpreting genetic
associations and/or expression patterns in the context of pathway
analyses etc. Conversely, we used genotypes independently of
being strong risk factors or showing phenotype association to study
functional hypotheses such as a role of a particular cytokine-
receptor system (IL-2) or cell type (aTregs) in a defined physiologic
context. Our results suggest that genetic information in human
populations can indeed be indirectly used in this way to interpret
functionality, without necessarily following the traditional strate-
gies of genetic study that are not based on functionally defined
hypotheses. Systematically applied, this may open a totally new
perspective of physiologic modeling, particularly in contexts that
are not easily accessible to direct experimentation. In this way, our
approach also revives the concept of subphenotype analysis in
genetics. We used autoantibody repertoires as a reference system
in our study, but it appears very exciting to apply the same analytic
approach e. g. to microarray-based genome-wide RNA expression
data. The dimensionality and depth of this and other types of data
available with high-throughput technologies could exceed our
reference system by orders of magnitude, and if coreferentiality-
based models on the basis of such reference systems are as capable
of delineating modules of functionally related effects as they
appeared to be in our study, this is expected to have great analytic
power.
Materials and Methods
Sample
128 SLE patients, 215 unaffected relatives and 20 unrelated
spouses from 61 SLE-affected families, as well as 120 healthy
blood donors were studied. Patients met the revised 1997
American College of Rheumatology criteria for SLE (Hochberg,
1997). The study was approved by the Ethics Committee of the
Portuguese Lupus Patients Association, and written informed
consent was obtained from all participants. Collections took place
2001–2004. For analysis, blood donors and unrelated spouses were
cumulated in the group of unrelated healthy control subjects. Age
and gender distributions are shown in Table 1. At collection, in
order to address possibly undiagnosed subclinical SLE in
unaffected relatives, they answered ten simple questions [67].
However, no autoantibody reactivity measure described was
positively correlated with the number of positively answered
questions.
Plasma preparation, protein quantification and
quantitative ELISA
Peripheral blood was collected in 7,5 mL Vacutainer CPT tubes
containing citrate (Becton Dickinson) and centrifuged. Plasma
supernatants were aliquoted and stored at 220uC. Total protein
concentrations were determined by the Biuret method in an
automated system (Hospital de Santa Cruz, Lisboa). Quantitative
ELISAs were performed as described [10]. Briefly, plates (Pierce)
were coated overnight with purified Ro60/SS-A (ImmunoVision)
or dsDNA (Sigma-Aldrich), blocked with PBS-Gelatin 1%, and
incubated overnight at 4uC with test plasma diluted in PBS
containing 1% gelatin and 0.1% Tween-20 (for dsDNA without
Tween) so that the final total protein concentration was always
0,5 mg/mL. After washing, plates were incubated overnight with
alkaline phosphatase-conjugated anti-human IgG (Sigma-Aldrich)
diluted 1:1000, reactivity revealed with p-nitrophenyl phosphate
(Sigma-Aldrich) and 405 nm absorbance measured by an ELISA
plate reader (BioRad). Quantification was obtained by fitting ODs
to a standard curve present in duplicates on each plate, consisting
of 12 serial dilutions of positive control sera (ImmunoVision). One
unit of reactivity was defined as the equivalent of the highest
control serum concentration, previously chosen to be below
saturation level.
Quantitative immunoblot
Quantitative immunoblot was essentially carried out according
to [30,32], with recent adaptations by us [38,39]. Briefly, nuclei
and cytoplasm of trypsinized cultured HEp2 cells were separated
[68], and nuclei further purified by Ficoll 12.5–25% gradient
ultracentrifugation. Nuclear and cytoplasmic preparations, as well
as human brain tissue obtained from a deceased person without
preceding brain disease, were mechanically homogenized and
solubilized, separated by 10% SDS-PAGE, electrotransferred onto
nitrocellulose membranes and blocked as described [32]. Mem-
branes were then incubated with plasma samples diluted in PBS/
0.2% Tween-20 so that the final total protein concentration was
1 mg/mL, using a cassette system (Immunetics, Cambridge, MA)
with separate incubation slots allowing to assay 24 samples per
membrane. On every membrane, there were two replicates of a
general reactivity standard (a mixture of plasma samples reactive
to many bands, prepared in large quantity) and a quality control
(Fig. S1). Samples were randomly distributed over the membranes.
Incubation was for 4 h at room temperature, followed by detection
by alkaline phosphatase-coupled chain-specific rabbit anti-human
IgG (Sigma-Aldrich) for 90 min at room temperature. After
revelation with NBT/BCIP, membranes were densitometrically
scanned (600 dpi, 8-bit linear grayscale), stained with colloidal gold
(Protogold, BritishBioCell, Cardiff, GB) for total protein, and
scanned again. As described [32], protein staining in the spaces
between incubation slots was used to adjust migration scales within
and between membranes. The resulting standardized scale was
divided into sections around immunoreactivity peaks. Peak areas
under the respective densitometric profiles above baseline level
were calculated for each section and divided by the section length.
These standardized densities were further subtracted by a
background density defined for each section and membrane as
the 25
th percentile of all samples assayed on the same membrane
(after verification that no visible reactivity band was recognized
distinguishably from background by .75% of the samples), and
normalized between membranes by division by the average
standardized density of all sections of the two reactivity standard
replicates present on each membrane. Given the random
distribution of samples over the membranes, this standardization
could be tested for possible artefacts by membrane-wise compar-
ison, and no significant difference was detected between the
respective 24 membranes blotted with the same extract (Kruskal-
Wallis test).
Quantitative immunoblot assays in this study were adjusted for
equal total plasma protein and not for total IgG as it was done in
earlier studies with this method that had aimed to characterize
naturally autoreactive repertoires and accordingly favored a
proportional representation. Since, in contrast, this study aimed
at representing and analyzing absolute levels of specific IgG as
conventional serology does, total plasma protein levels were used
for adjustment, which largely represent plasma albumin and not
the individual variations in total circulating IgG.
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Peripheral blood mononuclear cells (PBMC) were isolated using
Vacutainer CPT
TM tubes (Becton Dickinson). 1610
6 cells were
fixed in 2% paraformaldehyde, washed twice in PBS containing
2% fetal calf serum, and incubated for 20 min at 4uC with the
optimal dilution of each conjugated anti-human mAb (CD4-
FITC, CD31-PE, CD25-PE/Cy5 and CD45RO-APC, all from
Becton Dickinson). Cells were washed again and fluorescence
intensity measured using a FACScalibur flow cytometer and the
CellQuest
TM software. As a quantitative readout of aTregs,
without Foxp3 staining that was not available when this study was
done, but in consistency with their recent characterization [11],
frequencies of CD25
bright within CD4
+ cells were measured as
follows. First, in order to specify the upper limit of CD25 staining
in non-CD25-expressing cells for each sample, the ninety-ninth
percentile of PE/Cy5 fluorescence intensity within
CD4
2CD45RO
2 cells was determined. CD4
+CD25
bright aTregs
in the same sample were then quantified as those CD4
+ cells that
exceeded this value at least three-fold (Fig. 2).
Later, when intracellular Foxp3 staining was available, we
combined it (according to the instructions of ebioscience, the
manufacturer of the anti-Foxp3 staining kit) with CD4 and CD25
surface staining. The evaluation of this combination in 15 SLE
patients, 45 unaffected relatives and 54 blood donor controls
confirmed that the described aTreg gate (Fig. 2) regularly
contained similarly high proportions of Foxp3
+ cells in all three
groups: 8168% (SLE patients), 79611% (relatives) and 74613%
(controls). Particularly, the SLE patients did not show any
indication for increased contamination of gated CD25
bright by
Foxp3
2 cells, which can be seen in the individual cytograms of our
15 confirmatory stainings (Fig. S3).
Genotyping
Genomic DNA was extracted by standard methods. SNP
genotyping was performed on the Sequenom
TM platform using
multiplexed amplification followed by mass-spectrometric product
separation. For the IL2 SNPs rs2069762 and rs2069763,s o m e
samples that did not call were also typed by RFLP as described [69],
and the genotype information complemented accordingly. All SNPs
used were in Hardy-Weinberg equilibrium (P.0.01), indicated in
Table S1. HLA-DRB1 typing was performed by PCR sequence-
specific primers (PCR-SSP) using custom oligonucleotides, with
methods and primer sequences as described [70]. PCRproducts were
photographed over ultraviolet light after electrophoretic separation
on 1.5% agarose gels containing ethidium bromide. The method is
basedonthemultiplexedamplificationofbothanallele-specificanda
non-polymorphic sequence, used as internal control. Genotypes were
deduced from the amplification patterns. HLA types were ascribed to
a sample only when two alleles were amplified or, in the case of
homozygosity, when internal controls were positive.
Data analysis and statistics
Data analysis was performed on a Macintosh computer using
the software IgorPro (WaveMetrics) and specially written proce-
dures (Panama-Blot) for density quantification, migration scale
adjustment, section definition and standardization of immunoblot
data, as well as for statistics and coreferentiality calculations.
Genotype scores for SNPs were defined as the number of minor
alleles per individual (0, 1 or 2). For statistical testing, P values
below 0.05 were considered significant. Group comparisons were
performed by the distribution-independent Mann-Whitney or
Kruskal-Wallis tests. Correlations were in principle described and
tested for significance by distribution-independent Spearman rank
correlation coefficients. Group-wise median correlations with
immunoblot reactivities (Fig. 5), coreferentiality calculations and
the according modeling, however, were based on linear (Pearson)
correlations. Weighted correlations were used in order to adjust for
familiar relatedness, i.e., to avoid representation bias of genetic or
otherwise shared properties of related individuals, and to consider
each family/pedigree with an equal weight of one. Weights were
accordingly determined for each individual as the inverse of the
total number of subjects in this individual’s family/pedigree
considered in the respective calculation. Within unrelated control
subjects, no weighting was used since these subjects were all
unrelated to each other.
Coreferentiality coefficients RC between pairs of test parameters
were assessed and tested, resulting in a permutation P-value PPerm,a s
described [40], in respect to 130 quantified immunoblot reactivities
as reference data. First-order linear correlation coefficients in these
calculations were family-weighted, except within controls. For
coreferentiality with all SNPs in a locus simultaneously, an
analogous permutation test was performed that used the absolute
maximalcoreferentialityobtainedamongallconsideredSNPsasthe
test criterion instead of the absolute RC. Group-wise median
correlations were also tested analogously, with the median R as test
criterion. Bystander coreferentiality, i.e., the possibility that
coreferentiality was generated by direct correlation between the
test parameters with only one of them being related to the reference
data [40], was checked for significant coreferentiality tests (except
when for multiple SNPs) as follows. For each of the two test
parameters, 100 artificial second parameter data sets were
simulated, distributed N(0,10) and with family-weighted correla-
tions with the first parameter being equal (60.005) to those of the
true respective second test parameter. Each simulation was then
tested for coreferentiality, and the proportion of simulations
reaching the significance level of the true data determined. In
absence of a significant bystander effect, this proportion was
expected to remainbelow 5%.This wasalwaysfound to be the case.
Modeling
Modeling was based on coreferentiality maximization either
between a parameter and a function, or between two functions,
each function representing the linear combination of several SNP
genotype scores obtained from a respective locus. Functions had
the form flocus subject ðÞ ~
P
i
ciSScoreTi,subject, with i indicating the
SNPs considered, and ,Score. their respective genotype scores.
Coefficients ci were varied in order to maximize coreferentiality,
using the optimization algorithm ‘Amoeba’ adapted from [71]. For
coreferentiality maximization, we first applied this algorithm 20
times using independent random initial estimates, and further 15
times on the basis of already optimized coefficients from the
respective previous run as initial estimates, starting with those
giving the highest obtained coreferentiality among the 20 first runs
and stepwise tightening the convergence criterion. This procedure
was tested and robustly yielded identical models when repeated
with the same data and using up to 8 variable coefficients in the
functions. SNPs included in the models were selected as follows.
For the IL2 locus, we had good evidence that variant alleles of
rs11575812, rs2069762, and rs2069763 excluded each other in the
same haplotype (see discussion), and that their possible funcional
effects were consequently independent. Accordingly, we modeled
the IL2 genetic effect as the linear combination of these three
genotype scores. The effect of IL2RA genetic variation was
modeled by selecting, from total 25 SNPs typed (Table S1), five
(rs11594656, rs10795791, rs7073236, rs706778, rs791589) showing
absolute coreferentialities above 0.5 with the dominant IL2 SNP
rs11575812, disconsidering a sixth SNP (rs7072793) that also met
this criterion but was in almost complete LD with rs10795791.T o
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model optimization, for secondary calculations, respective func-
tions with the optimized model coefficients were applied to the
individual genotype scores. For this purpose, some missing
individual genotypes, not calling in Sequenom typing, were
imputed using the software fastPhase
TM. In order to model
CD247 genetic effects for secondary model comparison, among a
total of 24 SNPs typed, we selected three (rs858535, rs1737506,
rs863455) that had no evident linkage between each other but
covered the 59 region of the locus where many single SNPs had
high coreferentiality in the control group with the unaffected-
relatives optimized IL2RA model score.
Supporting Information
Figure S1 Example of a quantitative immunoblot mem-
brane. Each membrane is incubated with up to 28 plasma
samples, diluted to identical total protein concentrations of 1 mg/
mL. In the shown picture after substrate development, band
profiles of diverse individual samples can be seen. On each
membrane, two channels as indicated were reserved for a unique
reactivity standard serving to adjust resulting optical densities
between membranes. One further channel was always used for an
additional external quality control that was also present on a
second membrane.
(PDF)
Figure S2 Linkage disequilibrium map of the IL2 locus
according to our data (produced by HaploView). Anno-
tations indicate pairwise R
2 values.
(PDF)
Figure S3 Cytograms of confirmatory combined Foxp3/
CD25 stainings of 15 individual SLE patients. This figure is
included to demonstrate that possibly activated and CD25-
expressing Foxp3
2conventional T-helper cells do not significantly
contaminate the cells in our CD25
bright aTreg gate (R4) defined as
described in the methods. Inserts in each panel indicate the
respective proportions of Foxp3
+ within CD25
bright cells. The
uppest left cytogram, where Foxp3
2CD25
+ are most clearly
present, shows that this presence does not involve a reduced
proportion of Foxp3
+ cells in the aTregs that we analyze.
(PDF)
Table S1 Typed IL2, IL2RA and CD247 SNPs.
(PDF)
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